ACSC Scientific Program

Scientific program is subject to change. All times listed are MT (Mountain Time) and all events will take place at the Edmonton Convention Center unless otherwise indicated. Program items listed in the main plenary room (Hall B) will be broadcast live and recorded to be available at a later date.

(*SI) - Simultaneous interpretation will be available for this session (English/French) ; SI is only available to in-person participants.

All times given are in Mountain Daylight Time.

Printable program at-a-glance

No content found

No content found

No content found

No content found

These unaccredited sessions are offered in cooperation with our partners.
_
Room Name: Hall B

Tuesday, June 11
Prevention of venous thromboembolism in gynecological surgery

11:45 AM to 12:30 PM

Session Details

At the end of this session, participants will be able to:
  • Recognize that perioperative venous thrombosis is a cause of significant patient morbidity and mortality;
  • Examine preoperative consideration of VTE prophylaxis -the benefits and risks, including the risk of hemorrhage;
  • Recognize that options for thromboprophylaxis are diverse and can be combined to optimize prevention including mechanical prophylaxis;
  • Identify the need for the rationale for a chosen treatment to be documented;
  • Plan for their own institutions should adopt a standardized approach to risk assessment with accompanying order sets for peri and postoperative thromboprophylaxis.
Thank you to our partner, Cardinal Health, for making this educational session possible.
Speakers:
Room Name: Salon 4

Tuesday, June 11
Empower her: Taking control of AUB and IDA in patients with uterine fibroids

12:30 PM to 01:30 PM

Session Details

At the end of this session, participants will be able to:
  • Perform appropriate clinical assessment and diagnostic tests in patients presenting with abnormal uterine bleeding;
  • Optimize care of patients with uterine fibroids to minimize abnormal uterine bleeding and address quality of life issues;
  • Implement a multidisciplinary approach to determine when and how to replenish iron stores in patients with abnormal uterine bleeding and iron deficiency anemia.
Thank you to our partner, Pfizer, for making this educational session possible.
Speakers:
Room Name: Hall B

Wednesday, June 12
Non-accredited session: Inhaled analgesia for in-clinic gynecology

11:15 AM to 12:00 PM

Session Details

At the end of this session, participants will be able to:
  • Review of office gynecological procedures and literature review of present options for analgesia;
  • Educate and share clinical experience on the efficacy and safety of inhaled analgesic methoxyflurane for in clinic gynecology.
Thank you to our partner, Paladin Pharma Inc., for making this educational session possible.
Speakers:
Room Name: Salon 4

Wednesday, June 12
Panel: PCOS management in 2024: A lifetime journey

12:00 PM to 01:00 PM

Session Details

At the end of this session, participants will be able to:
  • Review the current thoughts on PCOS multisystem impact and emphasize the need for multidisciplinary care;
  • Discuss treatment options and a lifelong plan for PCOS management;
  • Explore fertility options for PCOS patients desiring fertility.
Thank you to our partner, BioSyent, for making this educational session possible.
Speakers:
Room Name: Hall B

Thursday, June 13
Empowering women in the management of GSM

11:15 AM to 12:00 PM

Session Details

At the end of this session, participants will be able to:
  • Recognize the key clinical features and physiology of genitourinary syndrome of menopause;
  • Describe the unmet needs and impact GSM can have on post-menopausal women;
  • Review the various treatment options available.
Thank you to our partner, Knight Therapeutics, for making this educational session possible.
Speakers:
Room Name: Salon 4

Thursday, June 13
Menopause is more than VMS: Focus on sleep and mood

12:00 PM to 01:00 PM

Session Details

At the end of this session, participants will be able to:
  • Outline the breadth of menopause symptoms with emphasis on sleep and mood in addition to VMS;
  • Discuss the association between VMS, sleep and mood;
  • Highlight the role of brain receptors, including new data showing the involvement on NK-1 and NK-3 receptor;
  • Outline various treatment options that address this triad.

Thank you to our partner, Bayer, for making this educational session possible.
Speakers:

No content found